GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Cathay Biotech Inc (SHSE:688065) » Definitions » Capital Expenditure

Cathay Biotech (SHSE:688065) Capital Expenditure : ¥-1,545.91 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cathay Biotech Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Cathay Biotech's cash flow for capital expenditures for the three months ended in Mar. 2024 was ¥-463 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-1,545.91 Mil.

Cathay Biotech Capital Expenditure Historical Data

The historical data trend for Cathay Biotech's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cathay Biotech Capital Expenditure Chart

Cathay Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial -511.14 -763.11 -1,459.18 -4,198.36 -1,569.78

Cathay Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -487.10 -281.02 -573.01 -228.66 -463.23

Cathay Biotech Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,545.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cathay Biotech (SHSE:688065) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Cathay Biotech Inc (SHSE:688065) » Definitions » Capital Expenditure
Comparable Companies
SHSE:601216 SZSE:002080 SHSE:600352 SHSE:600378 SZSE:300487 SZSE:003022 SZSE:000818 SZSE:000683 SZSE:300769 SHSE:600160 SAU:2010 TSE:4063 XTER:BAS DOW XKRX:051910 SZSE:002493 SHSE:600989 XKRX:086520 CE XKLS:5183
Traded in Other Exchanges
N/A
Address
1690 Cailun Road, 4th Floor, Building 5, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Website
https://www.cathaybiotech.com
Cathay Biotech Inc is engaged in production of revolutionary products, including bio-based polyamide,bio-based DN5 (1,5-pentanediamine), long chain dibasic acids (LCDA) and biobutanol. The company's commercial development platform focuses on research of molecular biology, fermentation process engineering, polymer material. Its products include Dibasic Acids, Pentamethylene Diamine, and Bio-based Polyamide.

Cathay Biotech (SHSE:688065) Headlines

No Headlines